Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vapiprost SCHEMBL9344105 | 1.00 | TBXA2R (1.00) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL8895507 | 1.00 | TBXA2R (1.00) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL28550 | 1.00 | TBXA2R (1.00) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL9342604 | 1.00 | TBXA2R (1.00) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL28551 | 1.00 | TBXA2R (1.00) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL635146 | 0.99 | TBXA2R (0.98) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL635147 | 0.99 | TBXA2R (0.98) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL27984405 | 0.99 | TBXA2R (0.98) | TBXA2RMEN1KMT2ATBXAS1 | |
| Vapiprost SCHEMBL7833619 | 0.98 | TBXA2R (0.96) | TBXA2RMEN1KMT2ATBXAS1 | |
| SCHEMBL10489337 | 0.94 | TBXA2R (0.90) | TBXA2RMEN1KMT2ATBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0256805-A2 | Pharmaceutical compositions for the treatment of occlusive vascular diseases | GLAXO GROUP LIMITED (GB) | 1988-02-24 | — | — | EP | claimed |
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | disclosed |
| US-12161632-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230381147-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| US-20230270726-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | VANDERBILT UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| EP-3454850-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS | CUMBERLAND PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11571412-B2 | Thromboxane receptor antagonists in AERD/asthma | CUMBERLAND PHARMACEUTICALS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109152767-B | Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists | 坎伯兰医药品股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220218672-A1 | Thromboxane Receptor Antagonists in AERD/Asthma | CUMBERLAND PHARMACEUTICALS INC. (US) | 2022-07-14 | — | — | US | disclosed |
| EP-0234737-B1 | Preparation of piperidinylcyclopentylheptenoic acid derivatives | GLAXO GROUP LTD (GB) | 1994-07-27 | — | — | EP | disclosed |
| EP-0335627-A3 | USE OF A THROMBOXANE ANTAGONIST IN CYCLOSPORIN A-INDUCED NEPHROTOXICITY | GLAXO GROUP LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
| EP-0348150-A2 | Use of thromboxane receptor antagonist in renal diseases and dysfunction | GLAXO GROUP LIMITED (GB) | 1989-12-27 | — | — | EP | disclosed |
| EP-0335627-A2 | Use of a thromboxane antagonist in cyclosporin A-induced nephrotoxicity | GLAXO GROUP LIMITED (GB) | 1989-10-04 | — | — | EP | disclosed |
| US-4835278-A | Preparation of piperidinylcyclopentylheptenoic acid derivatives | GLAXO GROUP LIMITED (GB) | 1989-05-30 | — | — | US | disclosed |
| US-4613597-A | ANTICOAGULANTS, VASODILATORS, BRONCHODILATORS | GLAXO GROUP LIMITED (GB) | 1986-09-23 | — | — | US | disclosed |
| US-4530925-A | Aminocyclopentane esters and pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 1985-07-23 | — | — | US | disclosed |
| EP-0127930-A2 | Aminocyclopentane esters and their preparation and pharmaceutical formulation | GLAXO GROUP LIMITED (GB) | 1984-12-12 | — | — | EP | disclosed |
| EP-0069447-A2 | Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation | GLAXO GROUP LIMITED (GB) | 1983-01-12 | — | — | EP | disclosed |
| US-4342756-A | AS ANTITHROMBOTIC AGENTS AND ANTIASTHMATIC AGENTS | GLAXO GROUP LIMITED (GB) | 1982-08-03 | — | — | US | disclosed |